Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has been assigned an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $22.25.

A number of equities analysts have recently issued reports on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $31.00 price objective on shares of Neumora Therapeutics in a research note on Thursday, March 28th. Mizuho started coverage on Neumora Therapeutics in a research note on Monday. They set an “outperform” rating and a $20.00 price objective for the company. William Blair reaffirmed an “outperform” rating on shares of Neumora Therapeutics in a report on Friday, April 12th. Finally, JPMorgan Chase & Co. boosted their price objective on Neumora Therapeutics from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Monday, March 18th.

Neumora Therapeutics Price Performance

Shares of Neumora Therapeutics stock opened at $10.76 on Thursday. The firm has a fifty day moving average price of $9.62 and a two-hundred day moving average price of $13.21. Neumora Therapeutics has a fifty-two week low of $8.33 and a fifty-two week high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Tuesday, May 7th. The company reported ($0.34) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.34). As a group, analysts expect that Neumora Therapeutics will post -1.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Neumora Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in NMRA. Artal Group S.A. boosted its holdings in Neumora Therapeutics by 14.5% in the first quarter. Artal Group S.A. now owns 2,924,052 shares of the company’s stock valued at $40,206,000 after acquiring an additional 371,350 shares during the last quarter. Kennedy Capital Management LLC bought a new stake in shares of Neumora Therapeutics during the first quarter worth approximately $1,881,000. Baker BROS. Advisors LP bought a new stake in shares of Neumora Therapeutics during the first quarter worth approximately $8,715,000. Price T Rowe Associates Inc. MD acquired a new position in Neumora Therapeutics in the first quarter valued at approximately $10,354,000. Finally, Nan Fung Group Holdings Ltd bought a new position in Neumora Therapeutics in the first quarter valued at approximately $871,000. Institutional investors own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.